-
This Smart Monitor Company Has Outperformed Apple, Google And Amazon Over The Last 5 Years
Wednesday, September 8, 2021 - 6:00pm | 535Read More...A smart monitor company that received FDA approval in 2015 has seen a five-year stock performance that has outperformed the returns of Apple Inc (NASDAQ: AAPL), Alphabet Inc (NASDAQ: GOOG)(NASDAQ: GOOGL) and Amazon.com, Inc. (NASDAQ: AMZN). The company’s five-year outlook and guidance show...
-
5 New Medical Technologies For Diabetics
Friday, July 18, 2014 - 1:10pm | 788Read More...News of the recent partnership between European drugmaker Novartis (NYSE: NVS) and Google (NASDAQ: GOOG) (NASDAQ: GOOGL) to develop a contact lens designed to monitor blood sugar levels in diabetics has drawn attention to several other new diabetes treatment developments. Information Week...
-
Wedbush Reiterates Outperform and PT of $18 on DexCom
Thursday, June 30, 2011 - 8:31am | 39Read More...Wedbush reiterated its Outperform rating on DexCom (NASDAQ: DXCM). At the same time, Wedbush left its price target on the company's stock unchanged at $18. On Wednesday, DexCom closed teh day at $14.49.
-
Piper Jaffray Reiterates Overweight and PT of $20 on DexCom
Monday, June 27, 2011 - 6:18am | 46Read More...Piper Jaffray reiterated its Overweight rating on DexCom (NASDAQ: DXCM). At the same time, Piper Jaffray left its price target on the company's stock unchanged at $20. On Friday, DexCom lost 0.54% of its value to end the week at $14.60.
-
Jefferies Reiterates Buy On DexCom, Raises PT To $19.50 (DXCM)
Wednesday, May 4, 2011 - 1:00pm | 105Read More...Jefferies reiterated its Buy rating on DexCom (NASDAQ: DXCM), but raised price target on its shares from $17 to $19.50 in a research report published today. In the report, Jefferies states, "DexCom reported 1Q revenues of $14.2mn which was slightly shy of street forecasts, but earnings were in...
-
Wedbush Raises PT On DexCom To $18 After In-Line 1Q Results
Wednesday, May 4, 2011 - 9:05am | 144Read More...Wedbush Securities has published a research report on DexCom (NASDAQ: DXCM) after the company reported 1Q results that were in-line with analyst estimates. In the report, Wedbush writes "DXCM reported Q1:11 product revenue of $13.1 million (-3% Q/Q; +94% Y/Y) which was in-line with consensus. Our...
-
Jefferies Initiating Coverage On DexCom At Buy
Tuesday, March 29, 2011 - 7:52am | 123Read More...According to Jefferies, DexCom (NASDAQ: DXCM) is initiated with a Buy rating. Jefferies reported that DexCom offers the Seven Plus Sensor to continuously monitor glucose levels, allowing patients to better manage their glucose levels. “Adoption of CGM technology is still in its infancy with the...
-
Jefferies Initiates DexCom At Buy, $17 PT
Tuesday, March 29, 2011 - 7:10am | 24Read More...Jefferies & Company has initiated coverage on DexCom (NASDAQ: DXCM) with a Buy rating and $17 price target.
